Spelling suggestions: "subject:"hepatic encephalopathy"" "subject:"hepatic encephalopatphy""
1 |
Subklinische hepatische enzephalopathie entwicklung und erprobung einer rechnergestutten testbatterie zur psychometrischen diagnose /Wein, Christian. January 1996 (has links)
Thesis (Ph. D.)--Universität Hamburg, 1996. / eContent provider-neutral record in process. Description based on print version record. Includes bibliographical references.
|
2 |
Subklinische hepatische enzephalopathie entwicklung und erprobung einer rechnergestutten testbatterie zur psychometrischen diagnose /Wein, Christian. January 1996 (has links)
Thesis (Ph. D.)--Universität Hamburg, 1996. / Includes bibliographical references.
|
3 |
Tryptophan-related neurotransmission in the brain disturbances associated with experimental hepatic encephalopathy /Bergqvist, Peter B. F. January 1997 (has links)
Thesis (doctoral)--Lund University, 1997. / Added t.p. with thesis statement inserted.
|
4 |
Tryptophan-related neurotransmission in the brain disturbances associated with experimental hepatic encephalopathy /Bergqvist, Peter B. F. January 1997 (has links)
Thesis (doctoral)--Lund University, 1997. / Added t.p. with thesis statement inserted.
|
5 |
Neurotransmitter alterations in hepatic failure : influence of precursor distribution and blood-brain barrier transportMans, Anke Melisa 31 July 2017 (has links)
No description available.
|
6 |
A REGIONAL SURVEY DIRECTED TO STUDY THE USE OF PROTEIN RESTRICTION IN THE TREATMENT OF CHRONIC HEPATIC ENCEPHALOPATHYMACMULLEN, ANN E. 01 July 2004 (has links)
No description available.
|
7 |
Effects of a High Protein Diet and Liver Disease in an in Silico Model of Human Ammonia MetabolismGriffin, Jeddidiah W.D., Bradshaw, Patrick C. 31 July 2019 (has links)
BACKGROUND: After proteolysis, the majority of released amino acids from dietary protein are transported to the liver for gluconeogenesis or to peripheral tissues where they are used for protein synthesis and eventually catabolized, producing ammonia as a byproduct. High ammonia levels in the brain are a major contributor to the decreased neural function that occurs in several pathological conditions such as hepatic encephalopathy when liver urea cycle function is compromised. Therefore, it is important to gain a deeper understanding of human ammonia metabolism. The objective of this study was to predict changes in blood ammonia levels resulting from alterations in dietary protein intake, from liver disease, or from partial loss of urea cycle function. METHODS: A simple mathematical model was created using MATLAB SimBiology and data from published studies. Simulations were performed and results analyzed to determine steady state changes in ammonia levels resulting from varying dietary protein intake and varying liver enzyme activity levels to simulate liver disease. As a toxicity reference, viability was measured in SH-SY5Y neuroblastoma cells following differentiation and ammonium chloride treatment. RESULTS: Results from control simulations yielded steady state blood ammonia levels within normal physiological limits. Increasing dietary protein intake by 72% resulted in a 59% increase in blood ammonia levels. Simulations of liver cirrhosis increased blood ammonia levels by 41 to 130% depending upon the level of dietary protein intake. Simulations of heterozygous individuals carrying a loss of function allele of the urea cycle carbamoyl phosphate synthetase I (CPS1) gene resulted in more than a tripling of blood ammonia levels (from roughly 18 to 60 μM depending on dietary protein intake). The viability of differentiated SH-SY5Y cells was decreased by 14% by the addition of a slightly higher amount of ammonium chloride (90 μM). CONCLUSIONS: Data from the model suggest decreasing protein consumption may be one simple strategy to decrease blood ammonia levels and minimize the risk of developing hepatic encephalopathy for many liver disease patients. In addition, the model suggests subjects who are known carriers of disease-causing CPS1 alleles may benefit from monitoring blood ammonia levels and limiting the level of protein intake if ammonia levels are high.
|
8 |
Cerebral edema and acute liver failure : pathophysiological mechanisms and new therapeutic approachesJiang, Wenlei 03 1900 (has links)
L’encéphalopathie hépatique (EH) se développe chez les patients atteints d’une maladie du foie et se caractérise par de nombreuses anomalies neuropsychiatriques. L’insuffisance hépatique aiguë (IHA) se caractérise par une perte progressive de l’état de conscience, par une augmentation rapide de l’œdème cérébral et une augmentation de la pression intracrânienne entraînant une herniation cérébrale et la mort. Plusieurs facteurs sont responsables du développement de l’EH mais depuis une centaine d’années, l’hyperammonémie qui peut atteindre des concentrations de l’ordre de plusieurs millimolaires chez les patients atteints d’IHA aux stades de coma est considérée comme un facteur crucial dans la pathogenèse de l’EH.
La présente thèse comprend 4 articles suggérant l’implication de nouveaux mécanismes pathogéniques dans le développement de l’EH et de l’œdème cérébral associés à l’IHA et tente d’expliquer l’effet thérapeutique de l’hypothermie et de la minocycline dans la prévention de l’EH et de l’œdème cérébral:
1. L’IHA induite par dévascularisation hépatique chez le rat se caractérise par une augmentation de la production de cytokines pro-inflammatoires cérébrales (IL-6, IL-1, TNF-). Cette observation constitue la première évidence directe que des mécanismes neuro-inflammatoires jouent une rôle dans la pathogenèse de l’EH et de l’œdème cérébral associés à l’IHA (Chapitre 2.1, articles 1 et 2).
2. L’activation de la microglie telle que mesurée par l’expression de marqueurs spécifiques (OX42, OX-6) coïncide avec le développement de l’encéphalopathie (stade coma) et de l’œdème cérébral et s’accompagne d’une production accrue de cytokines pro-inflammatoires cérébrales (Chapitre 2.1, article 1 et 2).
3. Un stress oxydatif/nitrosatif causé par une augmentation de l’expression de l’oxyde nitrique synthétase et une augmentation de la synthèse d’oxyde nitrique cérébral participe à la pathogénèse des complications neurologiques de l’IHA (Chapitre 2.3, articles 3 et 4).
4. Des traitements anti-inflammatoires tels que l’hypothermie et la minocycline peuvent constituer de nouvelles approches thérapeutiques chez les patients atteints d’IHA (Chapitre 2.1, article 1; Chapitre 2.2, article 2).
5. Les effets bénéfiques de l’hypothermie et de la minocycline sur les complications neurologiques de l’IHA expérimentale s’expliquent, en partie, par une diminution du stress oxydatif/nitrosatif (Chapitre 2.3, article 3; Chapitre 2.4, article 4). / Hepatic encephalopathy (HE) contains a spectrum of neuropsychiatric abnormalities observed in patients with liver disease. A quick worsening of consciousness and increasingly growing cerebral edema, high intracranial pressure, which leads to cerebral herniation and death, are characteristics of acute liver failure (ALF). Multiple factors are found responsible for the development of HE, whereas, over 100 years, hyperammonia is considered the most crucial factor in defining the pathogenesis of HE in ALF, which can increase to millimolar concentrations in the brain at the coma stages of HE.
The present thesis comprises 4 articles, which demonstrates new pathogenic mechanisms involved in the development of HE and cerebral edema in ALF, and elucidates part of the therapeutic mechanism of hypothermia and minocycline in the prevention of HE and cerebral edema during ALF. The major findings are listed below:
(1) Experimental ALF leads to the increase in brain production of proinflammatory cytokines (IL-6, IL-1, TNF-α), and provides the first direct evidence that central inflammatory mechanisms play a role in the pathogenesis of the encephalopathy and brain edema in ALF (chapter 2.1 - article 1; chapter 2.1 - article 2).
(2) Activation of cerebral microglia, measured by OX-42, OX-6, predicts the presence of severe encephalopathy (coma) and brain edema in rats with ischemic ALF, which accompanies the increased production of brain proinflammatory cytokines (chapter 2.1 - article 1; chapter 2.2 - article 2).
(3) Oxidative/nitrosative stress participates in the pathogenesis of brain edema and its complications in experimental ALF animals with ischemic liver failure. The increases in cerebral NOS isoform expression caused by ALF were sufficient to cause increased NO production in the brain (chapter 2.3 - article 3; chapter 2.4 - article 4).
(4) Anti-inflammatory treatment, such as hypothermia or antibiotics, may be beneficial in patients with ALF (chapter 2.1 - article 1; chapter 2.2 - article 2).
(5) The beneficial effect of both hypothermia and minocycline on the neurological complications of experimental ALF is mediated, at least in part, by reduction of brain-derived oxidative/nitrosative stress (chapter 2.3 - article 3; chapter 2.4 - article 4).
|
9 |
Qual dos aminoácidos de cadeia ramificada aumenta o fluxo cerebral na encefalopatia hepática? Ensaio clínico randomizado e duplo-cegoAugusti, Lais. January 2018 (has links)
Orientador: Fernando Gomes Romeiro / Resumo: Aminoácidos de cadeia ramificada aumentam a perfusão cerebral de pacientes com encefalopatia hepática (EH), mas o aminoácido responsável por esse aumento e os mecanismos envolvidos ainda não são conhecidos. Este estudo comparou a perfusão cerebral e a melhora clínica durante a suplementação de leucina ou isoleucina. Após a randomização, 27 indivíduos com cirrose e EH receberam suplementos de leucina ou isoleucina por um ano. Exames de tomografia computadorizada por emissão de fóton único (SPECT) e cintilografia cerebral dinâmica (DBS) foram realizados antes do estudo e após 1, 8 e 12 meses de suplementação. Apenas o grupo que recebeu isoleucina teve aumento da perfusão cerebral aos 8 meses de tratamento pelo exame de SPECT e pela cintilografia (p<0,001 e p = 0,05, respectivamente), também observado pelo SPECT aos 12 meses de suplementação (p < 0,05). O aumento do fluxo cerebral foi associado a melhora da EH aos 8 e 12 meses de suplementação (p=0,008 e 0,004, respectivamente), porém essa melhora não foi observada no grupo que recebeu leucina (p=0,313 e 0,055, respectivamente). A suplementação com isoleucina obteve melhor impacto na restauração da perfusão cerebral em pacientes com EH. / Abstract: Branched-chain amino acids increase the brain perfusion of patients with hepatic encephalopathy (HE), but the amino acid and the mechanisms involved are still unknown. This study compared brain perfusion and clinical improvement during leucine or isoleucine supplementation. After randomization, 27 subjects with cirrhosis and HE received leucine or isoleucine supplements for one year. Brain single photon emission computed tomography (SPECT) and dynamic brain scintigraphy (DBS) were performed pretreatment and at 1, 8 and 12 months of supplementation. Brain perfusion was increased only in the isoleucine group at 8 months of treatment by both SPECT and DBS (p<0.001 and p = 0.05, respectively) and by SPECT at the 12th month (p < 0.05). This was associated with hepatic encephalopathy improvement at 8 and 12 months (p=0.008 and 0.004, respectively), which was not observed in the leucine group (p=0.313 and 0.055, respectively). Isoleucine supplementation achieved a better impact on brain perfusion restoration in HE. / Doutor
|
10 |
Leucina versus isoleucina no tratamento da encefalopatia hepática ensaio clínico randomizado e duplo-cego /Franzoni, Letícia de Campos January 2017 (has links)
Orientador: Fernando Gomes Romeiro / Resumo: Introdução: Os aminoácidos de cadeia ramificada (BCAA) são parte do tratamento da encefalopatia hepática (HE) e aumentam a perfusão cerebral. Como são compostos por três aminoácidos diferentes, as proporções de cada um variam nos ensaios clínicos, tornando difícil esclarecer qual substância está mais envolvida na perfusão cerebral e em outros parâmetros significativos. O objetivo deste estudo foi comparar os efeitos clínicos e de perfusão cerebral obtidos pela suplementação de leucina versus isoleucina para tratamento da HE. Métodos: Cinqüenta pacientes ambulatoriais com cirrose e HE foram randomizados para receber suplementos orais contendo 30 g de leucina ou isoleucina diariamente, por um ano. As avaliações clínicas e a avaliação nutricional foram realizadas bimestralmente. A Tomografia Computadorizada cerebral por emissão de fóton único (SPECT) e a cintilografia cerebral dinâmica foram realizadas pré-tratamento e em 1, 8 e 12 meses de suplementação. Vinte e sete indivíduos concluíram o estudo (16 com isoleucina e 11 com leucina). Resultados: O aumento da perfusão cerebral foi observado apenas no grupo isoleucina. O aumento foi documentado aos 8 meses de tratamento tanto pelo SPECT como pela cintilografia cerebral (p <0,001 e p = 0,05, respectivamente) e pelo SPECT no 12º mês (p <0,05). Foi associado a uma melhora significativa de HE em 8 e 12 meses neste grupo (p = 0,008 e 0,004, respectivamente), o que foi menos claro no grupo leucina (p = 0,313 e 0,055, respectivamente).... (Resumo completo, clicar acesso eletrônico abaixo) / Doutor
|
Page generated in 0.0532 seconds